Overview

Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)

Status:
NOT_YET_RECRUITING
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
Intensive Lipid-Lowering Therapy guided by a cloud-based Software System (CLIMEDO GmbH) improves (European Society of Cardiolofgy/European Atherosclerosis Society) ESC/EAS-guideline recommended LDL-cholesterol target attainment and adherence in patients with ST-Elevation Myocardial (STEMI) and Non-ST-Elevation Myocardial Infarctions (NSTEMI).
Phase:
NA
Details
Lead Sponsor:
Jena University Hospital
Treatments:
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
alirocumab
ALN-PCS
evolocumab
Ezetimibe
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Nutrition Assessment